Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

WCLC 2024 Summary: Intensifying Suboptimal Response to Targeted Ther…

Insights from 2024 WCLC

M. Marmarelis

WCLC 2024 Insights: Long-Term Follow Up on Pembro + Itacitinib in PD…

Insights from 2024 WCLC

M. Marmarelis

A Multidisciplinary Team Approach to TTP

Penn Medicine Abramson Cancer Center

D. Siegel

ESMO 2023 Summary: "The CLEVER Trial - Targeting Disseminated Dorman…

Insights from 2023 ESMO Annual Meeting

A. DeMichele

SOHO 2023 Results from the QuANTUM-First Trial: Impact of allo-HCT i…

SOHO 2023 Eleventh Annual Meeting

A. Perl

2023 ASCO® Direct Philadelphia: Phase 3 OVHIPEC-1 Trial Final Surviv…

Total Health

A. Smith

2023 ASCO® Direct Philadelphia: Phase 3 SHAPE Trial - Radical vs. Si…

Total Health

A. Smith

2023 ASCO® Direct Philadelphia: RUBY Trial Review - Dostarlimab + Ch…

Total Health

A. Smith

Metastatic NSCLC Updates - 2023 ASCO® Direct Philadelphia

Total Health

S. Kazmi

2023 ASCO® Direct Philadelphia: TRANSCEND CLL 004 Study - CLL/SLL Up…

Total Health

J. Svoboda

2023 ASCO® Direct Philadelphia: Phase 3 ZUMA-7 Study - R/R DLBCL Upd…

Total Health

J. Svoboda

2023 ASCO® Direct Philadelphia: Hodgkin Lymphoma Updates

Total Health

J. Svoboda

Surgical Management of CRC Liver Metastases - 2023 ASCO® Direct Phil…

Total Health

R. Roses

Perioperative Therapy for Early Stage NSCLC - Best of Lung 2023

Total Health

S. Kazmi

ADAURA Trial Update: Osimertinib in Resected EGFRm NSCLC - Best of L…

Total Health

S. Kazmi

Neoadjuvant Therapy for Resectable Melanoma

International Congress on Cancer Metastasis

G. Karakousis

Precision Medicine and IO Have Arrived for Cholangiocarcinoma: An Ov…

Penn Medicine Abramson Cancer Center

T. Karasic

Treatment Strategies in ALL: Journey to MRD Negativity

Penn Medicine Abramson Cancer Center

C. Lai

ASCO GI 2023 Exploring Immunotherapy Combinations for DDR-Deficient …

ASCO GI 2023 Conference Coverage

K. Reiss Binder

The Role of Adjuvant Targeted Therapy in rNSCLC

Penn Medicine Abramson Cancer Center

M. Marmarelis

2022 Delivery of Care for Cancer Patients During the COVID-19 Pandem…

Penn Medicine Abramson Cancer Center

L. Schuchter

Update on Treatment of COVID-19 Infection for Cancer and Other Immun…

Penn Medicine Abramson Cancer Center

K. Murphy

Update on Treatment and Prevention of COVID-19 in Cancer Patients

Penn Medicine Abramson Cancer Center

A. Garfall

Penn Medicine Updates on the Advances in BRCA-Related Breast Cancer …

Penn Medicine Abramson Cancer Center

S. Domchek

Updates and Management of Medullary Thyroid Cancer: Genetic Testing …

Penn Medicine Abramson Cancer Center

V. Livolsi, K. Nathanson, L. L. Sun, R. Kelz, S. Mandel

Advances in Adjuvant Therapy in NSCLC

Penn Medicine Abramson Cancer Center

C. Ciunci

47 y/o Male With Papillary Thyroid Cancer: How to Plan Surgery Strat…

Penn Medicine Abramson Cancer Center

S. Mandel, A. Chalian, S. Swisher-Mcclure

47 y/o Male With Papillary Thyroid Cancer: Radioiodine-131 Planning …

Penn Medicine Abramson Cancer Center

S. Mandel, D. Pryma

47 y/o Male With High-Risk Thyroid Cancer: How Does Surveillance Wor…

Penn Medicine Abramson Cancer Center

S. Mandel, M. Brose

47 y/o Male With High-Risk Thyroid Cancer: What Is the Right Timing …

Penn Medicine Abramson Cancer Center

S. Mandel, M. Brose, A. Chalian, D. Pryma, S. Swisher-Mcclure

Attributes of Low-Risk Thyroid Cancer: How to Predict Risk? AJCC TNM…

Penn Medicine Abramson Cancer Center

S. Mandel

Low-Risk Thyroid Cancer Surgery Approach: What Are the Factors Influ…

Penn Medicine Abramson Cancer Center

H. Wachtel

The Histopathology of Low-Risk Thyroid Cancer: How to Assess and Ide…

Penn Medicine Abramson Cancer Center

J. Jalaly

Radioiodine Therapy for Low-Risk Thyroid Cancer: When Should I-131 T…

Penn Medicine Abramson Cancer Center

B. Cooperberg

Management of Low-Risk Thyroid Cancer: Is There a Difference in Recu…

Penn Medicine Abramson Cancer Center

S. Mandel

53 y/o Female With Papillary Thyroid Cancer, Two Suspicious R Latera…

Penn Medicine Abramson Cancer Center

B. Cooperberg, S. Mandel, H. Wachtel

UPenn 2020 ASCO Updates on Early Local Therapy in mBC: Does ELT Impr…

Penn Medicine Abramson Cancer Center

A. Mateo

UPenn 2020 ASCO Updates on HER2+ Ductal Carcinoma in Site: Does Tras…

Penn Medicine Abramson Cancer Center

A. Mateo

UPenn 2020 ASCO Updates on mTNBC: Does the Addition of Pembro to Che…

Penn Medicine Abramson Cancer Center

J. Matro

UPenn 2020 ASCO Updates on PARPi in mTNBC: Does Veliparib Improve Ch…

Penn Medicine Abramson Cancer Center

J. Matro

UPenn 2020 ASCO Updates on Operable TNBC: What Is the Role of Adjuva…

Penn Medicine Abramson Cancer Center

J. Matro

UPenn 2020 ASCO Updates on ET in MBC: Is Fulvestrant + Alpelisib Eff…

Penn Medicine Abramson Cancer Center

P. Gor

UPenn 2020 ASCO Updates on Adjuvant ET in BC: In Pts Treated With an…

Penn Medicine Abramson Cancer Center

P. Gor

Updates on HER2+ MBC: HER2CLIMB OS/PFS Data on Tucatinib Combo in Pa…

Penn Medicine Abramson Cancer Center

H. Knollman

UPenn Updates on HER2+ EBC: CT De-Escalation Using F-PET, Adjuvant T…

Penn Medicine Abramson Cancer Center

T. D'Entremont

UPenn 2020 ASCO Updates on Stage 2/3 HER2+ BC: Do Anthracyclines Imp…

Penn Medicine Abramson Cancer Center

H. Knollman

UPenn 2020 ASCO Updates on Adjuvant ET in BC: Does the 70-Gene Signa…

Penn Medicine Abramson Cancer Center

P. Gor

UPenn 2020 ASCO Breast Cancer Q&A: Preoperative Anthracyclines for H…

Penn Medicine

H. Knollman, A. Mateo, J. Matro, T. D'Entremont

TumorGlow®: Illuminating Cancer Cells in the Operating Room

Penn Medicine Abramson Cancer Center

Advances in Precision Surgery with Penn Medicine’s TumorGlow™ Techno…

Penn Medicine Abramson Cancer Center

S. Singhal